治疗高血压|从心衰转战高血压,ARNI类药物治疗前景值得期待!( 二 )


参考资料:
1.Wang Z,Chen Z,Zhang L,et al.Status ofHypertension in China:Results From the China Hypertension Survey,2012-2015[J].Circulation,2018,137(22):2344-56.10.1161/CIRCULATIONAHA.117.032380
2.Circulation.2018 Feb 15.pii:CIRCULATIONAHA.117.032380
3.胡大一等.中华心血管病杂志.2010;28(3):230-238;
4.Emdin CA,et al.JAMA.2015 Feb 10;313(6):603-15.
5.Wolfgang Lieb,J Am Heart Assoc.2015 Nov 20;4(11):e002155.
6.Bloch MJ,Basile JN.Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone[J].J Clin Hypertens(Greenwich),2010,12(10):809-12.10.1111/j.1751-7176.2010.00358.x
7.Gu J,Noe A,Chandra P,et al.Pharmacokinetics and pharmacodynamics of LCZ696,a novel dual-acting angiotensin receptor-neprilysin inhibitor(ARNi)[J].J Clin Pharmacol,2010,50(4):401-14.10.1177/0091270009343932
8.McMurray JJ,et al.N Engl J Med.2014 Sep 11;371(11)993-1004
9.Solomon SD,et al.JACC Heart Fail 2017;5(7):471-482.
10.Burkert Pieske,et al Presented at ESC Congress 2020
- End -

推荐阅读